Radiographic damage and progression of the cervical spine in ankylosing spondylitis patients treated with TNF-α inhibitors: Facet joints vs. vertebral bodies

Semin Arthritis Rheum. 2017 Apr;46(5):562-568. doi: 10.1016/j.semarthrit.2016.11.003. Epub 2016 Nov 9.

Abstract

Objectives: To investigate radiographic damage and 4-year progression of the cervical facet joints in a prospective observational cohort of AS patients treated with TNF-α inhibitors, to compare this with damage and progression of the cervical vertebral bodies, and to study the relation with patient characteristics and clinical outcome.

Methods: Patients from the Groningen Leeuwarden AS (GLAS) cohort starting TNF-α inhibitors with baseline and 4-year radiographs were included. Cervical facet joints and vertebral bodies were scored by two independent readers according to the method of de Vlam and mSASSS, respectively.

Results: At baseline, 25 of 99 (25%) AS patients had partial or complete ankylosis of the cervical facet joints, whereas 51 (52%) patients had non-bridging or bridging syndesmophytes of cervical vertebral bodies. During 4 years, 13 (13%) patients developed new (partial) ankylosis of the facet joints, whereas 26 (26%) developed new (bridging) syndesmophytes. Facet joint damage and progression without involvement of the vertebral bodies were seen in 5 (5%) and 8 (8%) patients, respectively. Damage of facet joints was associated with longer disease duration, history of IBD/uveitis/psoriasis, higher disease activity, larger occiput-to-wall distance, higher mSASSS, and presence of syndesmophytes. Progression of the facet joints was associated with larger occiput-to-wall distance and more facet joint damage at baseline.

Conclusions: Cervical facet joints were frequently involved in AS. During 4 years of TNF-α blocking therapy, 13% of the patients showed radiographic progression of cervical facet joints of which the majority did not show progression of vertebral bodies.

Keywords: Ankylosing spondylitis; Bone formation; Radiographic progression; Tumor necrosis factor-alpha blocking therapy; Zygapophyseal joint.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / therapeutic use
  • Adult
  • Anti-Inflammatory Agents / therapeutic use
  • Cervical Vertebrae / diagnostic imaging
  • Cervical Vertebrae / pathology
  • Cervical Vertebrae / physiopathology*
  • Disease Progression*
  • Female
  • Humans
  • Infliximab / therapeutic use
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prospective Studies
  • Radiography
  • Spondylitis, Ankylosing / diagnostic imaging
  • Spondylitis, Ankylosing / drug therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Zygapophyseal Joint / diagnostic imaging
  • Zygapophyseal Joint / pathology
  • Zygapophyseal Joint / physiopathology*

Substances

  • Anti-Inflammatory Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab